IL133626A0 - Treatment of insulin resistance with growth hormone secretagogues - Google Patents
Treatment of insulin resistance with growth hormone secretagoguesInfo
- Publication number
- IL133626A0 IL133626A0 IL13362698A IL13362698A IL133626A0 IL 133626 A0 IL133626 A0 IL 133626A0 IL 13362698 A IL13362698 A IL 13362698A IL 13362698 A IL13362698 A IL 13362698A IL 133626 A0 IL133626 A0 IL 133626A0
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- growth hormone
- insulin resistance
- hormone secretagogues
- secretagogues
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15411698A IL154116A0 (en) | 1997-06-25 | 1998-06-05 | Sythesis of intermediates for the preparation of growth hormone secretagogues |
| IL15411298A IL154112A0 (en) | 1997-06-25 | 1998-06-05 | Synthesis of intermediates for the preparation of growth hormone secretagogues |
| IL15411598A IL154115A0 (en) | 1997-06-25 | 1998-06-05 | Process for the preparation of growth hormone secretagogues |
| IL15411198A IL154111A0 (en) | 1997-06-25 | 1998-06-05 | Synthesis of intermediates for the preparation of growth hormone secretagogues |
| IL15646598A IL156465A (en) | 1997-06-25 | 1998-06-05 | Scrotagogens of growth hormone for use in the treatment of sleep disorders |
| IL15411498A IL154114A0 (en) | 1997-06-25 | 1998-06-05 | Composition for use as a medicament for increasing levels of endogeneous growth hormone |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5079097P | 1997-06-25 | 1997-06-25 | |
| PCT/IB1998/000876 WO1998058949A1 (en) | 1997-06-25 | 1998-06-05 | Treatment of insulin resistance with growth hormone secretagogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL133626A0 true IL133626A0 (en) | 2001-04-30 |
Family
ID=21967444
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13362698A IL133626A0 (en) | 1997-06-25 | 1998-06-05 | Treatment of insulin resistance with growth hormone secretagogues |
| IL15411598A IL154115A0 (en) | 1997-06-25 | 1998-06-05 | Process for the preparation of growth hormone secretagogues |
| IL15411298A IL154112A0 (en) | 1997-06-25 | 1998-06-05 | Synthesis of intermediates for the preparation of growth hormone secretagogues |
| IL15411498A IL154114A0 (en) | 1997-06-25 | 1998-06-05 | Composition for use as a medicament for increasing levels of endogeneous growth hormone |
| IL15411198A IL154111A0 (en) | 1997-06-25 | 1998-06-05 | Synthesis of intermediates for the preparation of growth hormone secretagogues |
| IL15411698A IL154116A0 (en) | 1997-06-25 | 1998-06-05 | Sythesis of intermediates for the preparation of growth hormone secretagogues |
| IL15646598A IL156465A (en) | 1997-06-25 | 1998-06-05 | Scrotagogens of growth hormone for use in the treatment of sleep disorders |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15411598A IL154115A0 (en) | 1997-06-25 | 1998-06-05 | Process for the preparation of growth hormone secretagogues |
| IL15411298A IL154112A0 (en) | 1997-06-25 | 1998-06-05 | Synthesis of intermediates for the preparation of growth hormone secretagogues |
| IL15411498A IL154114A0 (en) | 1997-06-25 | 1998-06-05 | Composition for use as a medicament for increasing levels of endogeneous growth hormone |
| IL15411198A IL154111A0 (en) | 1997-06-25 | 1998-06-05 | Synthesis of intermediates for the preparation of growth hormone secretagogues |
| IL15411698A IL154116A0 (en) | 1997-06-25 | 1998-06-05 | Sythesis of intermediates for the preparation of growth hormone secretagogues |
| IL15646598A IL156465A (en) | 1997-06-25 | 1998-06-05 | Scrotagogens of growth hormone for use in the treatment of sleep disorders |
Country Status (40)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| US6541634B2 (en) | 1999-02-26 | 2003-04-01 | Pfizer Inc. | Process for preparing growth hormone secretagogues |
| US7721948B1 (en) * | 1999-05-25 | 2010-05-25 | Silverbrook Research Pty Ltd | Method and system for online payments |
| EP1132388A3 (en) * | 2000-03-09 | 2004-03-03 | Pfizer Products Inc. | Hexahydropyrazolo[4,3-c]pyridine metabolites |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| CA2496687A1 (en) * | 2002-09-18 | 2004-04-01 | Centre Hospitalier De L'universite De Montreal (Chum) | Ghrh analogues |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| PT1828480E (pt) * | 2004-12-21 | 2014-08-29 | Hercules Inc | Resinas catiónicas reactivas para aplicação como agentes de resistência à secura e à humidade em sistemas de fabricação de papel contendo iões de sulfito |
| US20070024388A1 (en) * | 2005-07-27 | 2007-02-01 | Hassan Tanbakuchi | Slabline structure with rotationally offset ground |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| EA200901077A1 (ru) | 2007-02-09 | 2010-04-30 | Транзим Фарма, Инк. | Макроциклические модуляторы грелинового рецептора и их применение |
| US7862825B2 (en) * | 2007-02-21 | 2011-01-04 | Mladen Vranic | Method of controlling tight blood glucose by somatostatin receptor antagonists |
| RU2403902C1 (ru) * | 2009-06-15 | 2010-11-20 | Илья Николаевич Медведев | Способ снижения биологического возраста при нарушении толерантности к глюкозе |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| MA20150428A1 (fr) | 2012-05-03 | 2015-11-30 | Novartis Ag | Sel de l-malate de dérivés de 2,7-diaza-spiro[4.5]déc-7-yle et ses formes cristallines à titre d'agonistes des récepteurs de ghreline |
| TWI629982B (zh) * | 2013-05-28 | 2018-07-21 | 拉夸里亞創藥股份有限公司 | 多晶型形式 |
| US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
| US9873695B2 (en) * | 2014-08-05 | 2018-01-23 | Raqualia Pharma Inc. | Serine derivatives as ghrelin receptor agonists |
| JP2017532350A (ja) * | 2014-10-31 | 2017-11-02 | ラクオリア創薬株式会社 | グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体 |
| US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
| CN120265641A (zh) * | 2023-04-21 | 2025-07-04 | 长春金赛药业有限责任公司 | GHSR 1a激动剂、药物组合物及其制备方法和应用 |
| CN119285632A (zh) * | 2024-10-09 | 2025-01-10 | 威海中腾医药科技有限公司 | 一种基于酵母醇脱氢酶催化氧化的卡普瑞林中间体的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3235550A (en) | 1966-02-15 | Anal g gesiaxoat t tail intravenous injection | ||
| US3202660A (en) | 1961-10-09 | 1965-08-24 | Boehringer Sohn Ingelheim | Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes |
| US4411890A (en) | 1981-04-14 | 1983-10-25 | Beckman Instruments, Inc. | Synthetic peptides having pituitary growth hormone releasing activity |
| GB2101114B (en) | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| US5242783A (en) | 1991-07-31 | 1993-09-07 | Eastman Kodak Company | Photographic material and process |
| JPH08503213A (ja) | 1992-11-06 | 1996-04-09 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモンの放出を促進する置換ジペプチド同族体 |
| HUT72076A (en) | 1992-12-11 | 1996-03-28 | Merck & Co Inc | Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them |
| CZ134296A3 (en) | 1993-11-09 | 1996-12-11 | Merck & Co Inc | Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof |
| US5492916A (en) * | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
| EP0766966A3 (en) | 1995-09-08 | 2001-02-28 | Eli Lilly And Company | Method of treating insulin resistance |
| WO1997023508A1 (en) | 1995-12-22 | 1997-07-03 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| UA53716C2 (uk) | 1997-06-25 | 2003-02-17 | Пфайзер Продактс Інк. | Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти) |
| US6251902B1 (en) * | 1997-06-25 | 2001-06-26 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
-
1998
- 1998-05-06 UA UA99127068A patent/UA64751C2/uk unknown
- 1998-06-04 HN HN1998000088A patent/HN1998000088A/es unknown
- 1998-06-05 JP JP11504029A patent/JP2000514099A/ja not_active Withdrawn
- 1998-06-05 EP EP98921683A patent/EP1000085B1/en not_active Expired - Lifetime
- 1998-06-05 IL IL13362698A patent/IL133626A0/xx unknown
- 1998-06-05 CN CNB988059231A patent/CN1152049C/zh not_active Expired - Fee Related
- 1998-06-05 IL IL15411598A patent/IL154115A0/xx unknown
- 1998-06-05 IL IL15411298A patent/IL154112A0/xx unknown
- 1998-06-05 ES ES98921683T patent/ES2248899T3/es not_active Expired - Lifetime
- 1998-06-05 PL PL98337659A patent/PL337659A1/xx unknown
- 1998-06-05 IL IL15411498A patent/IL154114A0/xx unknown
- 1998-06-05 IL IL15411198A patent/IL154111A0/xx unknown
- 1998-06-05 ID IDW991668A patent/ID24345A/id unknown
- 1998-06-05 NZ NZ500655A patent/NZ500655A/en unknown
- 1998-06-05 CA CA002294464A patent/CA2294464A1/en not_active Abandoned
- 1998-06-05 YU YU70199A patent/YU70199A/sh unknown
- 1998-06-05 WO PCT/IB1998/000876 patent/WO1998058949A1/en not_active Application Discontinuation
- 1998-06-05 HU HU0001922A patent/HUP0001922A3/hu unknown
- 1998-06-05 EA EA199901075A patent/EA002089B1/ru not_active IP Right Cessation
- 1998-06-05 BR BRPI9810477-2A patent/BR9810477A/pt not_active Application Discontinuation
- 1998-06-05 SK SK1756-99A patent/SK175699A3/sk unknown
- 1998-06-05 KR KR1019997012312A patent/KR20010014224A/ko not_active Ceased
- 1998-06-05 AU AU74456/98A patent/AU747510B2/en not_active Ceased
- 1998-06-05 IL IL15411698A patent/IL154116A0/xx unknown
- 1998-06-05 AT AT98921683T patent/ATE305477T1/de not_active IP Right Cessation
- 1998-06-05 CN CNA2004100334189A patent/CN1530107A/zh active Pending
- 1998-06-05 PA PA19988452601A patent/PA8452601A1/es unknown
- 1998-06-05 TR TR1999/03257T patent/TR199903257T2/xx unknown
- 1998-06-05 US US09/380,186 patent/US6448263B1/en not_active Expired - Fee Related
- 1998-06-05 DE DE69831745T patent/DE69831745T2/de not_active Expired - Fee Related
- 1998-06-05 IL IL15646598A patent/IL156465A/en not_active IP Right Cessation
- 1998-06-18 AP APAP/P/1998/001267A patent/AP1145A/en active
- 1998-06-22 TW TW087110014A patent/TW553943B/zh not_active IP Right Cessation
- 1998-06-22 PE PE1998000546A patent/PE105399A1/es not_active Application Discontinuation
- 1998-06-23 EG EG73598A patent/EG21712A/xx active
- 1998-06-23 AR ARP980103023A patent/AR012256A1/es not_active Application Discontinuation
- 1998-06-24 DZ DZ980149A patent/DZ2539A1/xx active
- 1998-06-24 IN IN1755DE1998 patent/IN189724B/en unknown
- 1998-06-24 TN TNTNSN98113A patent/TNSN98113A1/fr unknown
- 1998-06-24 MA MA25139A patent/MA24581A1/fr unknown
- 1998-06-25 CO CO98036379A patent/CO4950621A1/es unknown
- 1998-06-25 HR HR60/050,790A patent/HRP980361A2/hr not_active Application Discontinuation
- 1998-06-25 ZA ZA9805546A patent/ZA985546B/xx unknown
-
1999
- 1999-11-26 IS IS5275A patent/IS5275A/is unknown
- 1999-12-14 BG BG104008A patent/BG104008A/xx unknown
- 1999-12-15 NO NO996205A patent/NO996205L/no not_active Application Discontinuation
- 1999-12-21 OA OA9900300A patent/OA11242A/en unknown
-
2002
- 2002-05-29 US US10/158,649 patent/US6630487B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/626,198 patent/US6867202B1/en not_active Expired - Fee Related
-
2004
- 2004-08-04 JP JP2004228301A patent/JP3742643B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL156465A0 (en) | Treatment of insulin resistance with growth hormone secretagogues | |
| EP0741578A4 (en) | HUMAN GROWTH HORMONE | |
| IL128128A (en) | Composition comprising insulin and insulin-like growth factor (i-igf) | |
| HU9601013D0 (en) | Combination of bisphosphonates and growth hormone secretagogues | |
| GB2324734B (en) | Catheter and needle assemblies | |
| HUP9802580A3 (en) | Compounds with growth hormone releasing properties | |
| EP1056514A4 (en) | ENDOLUMINAL IMPLANT WITH THERAPEUTIC AND DIAGNOSTIC CAPABILITIES | |
| EP0956057A4 (en) | INFUSION DEVICE WITH DISPOSABLE ELEMENTS | |
| ZA987383B (en) | Treatment of congestive heart failure with growth hormone secretagogues. | |
| PL338883A1 (en) | Growth hormone secretion stimulating compounds | |
| EP0688570A3 (de) | Insulinspritze | |
| IL122371A0 (en) | Compounds with growth hormone releasing properties | |
| EP0709395A3 (en) | Preparation of Stable Insulin Analog Crystals | |
| HU9904384D0 (en) | Process and intermediates for growth hormone secretagogues | |
| IL144350A0 (en) | Growth hormone secretagogues | |
| AP9901718A0 (en) | Treatment of diabetes with rosiglitazone and insulin | |
| ZA961007B (en) | Compounds with growth hormone releasing properties | |
| EP1126854A4 (en) | BENZOAZEPINES AND THEIR ANALOGS AS MEANS THAT PROMOTE THE SECRETION OF THE GROWTH HORMONE | |
| ZA961008B (en) | Compounds with growth hormone releasing properties | |
| HUP9904175A3 (en) | Human growth gene and short stature gene region | |
| AU7609298A (en) | Treatment of heart failure with growth hormone | |
| SI1007085T1 (en) | Use of growth hormone in compositions for treating insulin resistance in the heart | |
| SI0935469T1 (en) | Use of growth hormone | |
| ZA967973B (en) | Human growth hormone variants | |
| AUPP582198A0 (en) | Modified human growth hormone |